Home Buyer’s Guide Jobs Conferences Fellowships Books
New Products and Services
This page contains announcements of new pathology products and services from advertisers. Most announcements are posted for 90 days and then removed. For more information, please contact us at PathOutSales@gmail.com or at 248/646-0325.
9 March 2010: bioTheranostics announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.
CancerTYPE ID predicts cancer origin in patients whose primary cancer was initially “unknown or uncertain” using conventional diagnostics. Knowing the site where the cancer originated impacts physicians’ therapeutic decisions, and the results of the CancerTYPE ID assay can help physicians select optimal therapies earlier in the diagnostic process. This new database enhances the ability of the CancerTYPE ID assay to discriminate between clinically relevant metastatic tumors occurring within the GI tract, head and neck, lung (squamous, non-squamous adenocarcinoma, and mesothelioma), and intestine, while incorporating coverage of certain tumor types that frequently present diagnostic challenges such as cholangiocarcinoma, ovarian-mucinous adenocarcinoma, and small intestinal carcinoma.
bioTheranostics is working on developing additional tests including prostate cancer prognosis and drug-response profiling. For more information please contact Wendy Johnson, Associate Director Marketing, bioTheranostics, 858-587-5887 or click here.
____________________________________________
11 February 2010: Pulmotype is a five antibody immunohistochemistry (IHC) test to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer (NSCLC) tumor specimens. The histologic classification of NSCLC has gained clinical importance because current targeted therapies show different clinical potency or toxicity dependent upon the histotype of the tumor. Currently, there is no widely accepted standard to differentiate between NSCLC sub-types.
Pulmotype was developed by screening candidate markers on 551 surgical specimens from a retrospective lung carcinoma cohort assembled at a regional US hospital. It was subsequently validated on three independent cohorts comprising over 1,100 NSCLC cases total. Pulmotype plays an important role in NSCLC diagnosis by complementing the morphological assessment already performed by pathologists when sufficient specimen is available, or by replacing morphologic assessment when the specimen is too sparse for morphologic interpretation. To read more about Pulmotype, click here.
Squamous Adenocarcinoma Adenocarcinoma with
EGFR Mutation
For additional questions, please contact Clarient Client Services at 1.888.443.3311 or click here for more information on Clarient.
____________________________________________
11 February 2010: Modern Pathology, the official journal of the United States and Canadian Academy of Pathology (USCAP), announces the following free articles in its February 2010 issue:
Gastric-type dysplasia in Barrett's esophagus
Kinase mutations in breast papillomas
Modern Pathology's main focus is original papers reporting innovative clinical and translational research in the pathology of human disease. Access to all content is FREE 12 months post-publication. Visit the journal website at www.modernpathology.org.
_______________________________________________
8 February 2010: Laboratory Investigation, the official journal of the United States and Canadian Academy of Pathology, presents the following free articles in its February 2010 issue:
Mir-21 and glioblastoma multiforme
Steatohepatitis-induced liver damage is reversible
Granzyme B in immunity and disease
Laboratory Investigation is an international journal owned by The United States and Canadian Academy of Pathology and edited by a board appointed by the Council of the Academy. Laboratory Investigation offers prompt publication of high-quality original research in all biomedical disciplines relating to the understanding of human disease and the application of new methods to the diagnosis of disease. Visit us online at Laboratory Investigation.
_______________________________________________
19 January 2010: The highly-flexible Leica SCN400 slide scanner makes the scanning and digitizing of complete slides fast and easy. Due to its speed and flexibility, it can eliminate the need for an additional scanner in the laboratory. With a slide capacity of 384 slides, the autoloader can hold and rapidly transfer all slides through the scanning process in one batch using up to eight different protocols. With just the click of a few buttons, the scanner is set to run; the user can walk away from the instrument to do other laboratory tasks. From overview to detail, with one scan, the Leica SCN400 quickly provides images up to 40x magnification; the average scanning time for 20x magnification is a mere 100 seconds.
The system administrator can control access to data by assigning various levels of security rights depending on a laboratory’s needs. Also, important specimen slides scans can be securely sent to locations around the world with the click of a button. People in remote locations can now easily share specimens and participate in tumor boards and other virtual meetings. *The Leica SCN400 is for research use only in the United States of America and the People's Republic of China.
For more information, contact: Molly Baker, Leica Microsystems, Inc. Phone: 847/405-0123, 800/248-0123, Fax: 847/405-0164, email: news@leica-microsystems.com, Website: www.leica-microsystems.com
_______________________________________________
12 January 2010: Providing fully automated IHC and ISH, and the ability to stain more slides in less time, the Leica Bond-III offers critically important advantages that help histologists, laboratory managers, and pathologists deliver better patient care. Designed for Lean Histology workflows, Bond-III’s superior speed significantly improves productivity and reduces turnaround time. The system features three additional robots for bulk fluid dispensing; stained slides are ready for pathologists more quickly. Three independent trays of ten slides each allow continuous parallel processing, and the system can perform IHC and ISH with multiple detection systems at the same time. The efficient Bond-III increases uptime and reduces waste.
Bond-III provides high-quality staining and total tissue care. Its patented Covertile™ technology provides gentle tissue handling and low volume, uniform reagent coverage throughout the staining process to preserve tissue integrity and minimize repeats. A full range of Bond ready-to-use antibodies, designed with Novocastra® Science, are optimized for Bond instruments to provide consistently high-quality staining. The high concentration of enzyme for each antibody assures that stains are crisp and well defined and provides highly sensitive detection and specificity without background staining. The flexibility of Bond-III’s advanced software allows easy customization and control of staining quality. The staining protocol can match the needs of a specific laboratory and pathologist.
For more information, contact: Molly Baker, Leica Microsystems, Inc. Phone: 847/405-0123, 800/248-0123, Fax: 847/405-0164, email: news@leica-microsystems.com, Website: www.leica-microsystems.com
_______________________________________________
24 December 2009: Clarient, Inc. announced that it has acquired Applied Genomics, Inc. According to Clarient’s Chief Executive Officer Ron Andrews, "The combination of these organizations populates the Clarient proprietary pipeline of cancer tests, including the planned commercial launch of an important lung cancer test, Pulmotype(R), in the first quarter of 2010, followed by a series of proprietary tests to be commercialized in the following 24 months across a range of cancers including lung, breast and ovarian." In addition to Pulmotype, AGI has a pipeline of cancer diagnostic, prognostic and theranostic tests at various stages of validation and planned commercialization. Theranostics are a class of tests that assist in the selection of therapies by determining an individual patient's reaction to a specific therapeutic drug. The portfolio of tests includes a theranostic that may predict the response of a patient's cancer to taxane therapy across a variety of cancers, including lung, breast and ovarian. AGI also has a breast cancer panel with proprietary markers that could be included in a future version of Clarient's Insight(R) Dx, as well as separate tests designed to determine the potential response of women with breast cancer to certain drugs and therapies.
For additional questions, please contact Clarient Client Services at 1.888.443.3311 or click here for more information on Clarient.
____________________________________________
21 December 2010: Confirming negative results for the Factor V:Q506 Leiden mutation wastes many dollars and laboratory hours each year. With the Pefakit® APC-R FV Leiden assay, your lab will efficiently and cost-effectively rule out all negative patient samples. Its quick turnaround time, low cost and included application protocols make the Pefakit® the easiest way to screen for APC-Resistance due to the FV Leiden mutation. Due to the unique design, this assay shows NO interferences from Heparin, Coumadin, Protein C or S variations, Lupus anticoagulants, Prothrombin or elevated Factor VIII levels!
Visit www.centerchem.com, call 203-822-9800 or email diagnostics@centerchem.com for more information.
____________________________________________
22 December 2009: Leica Microsystems’ parent company, Danaher Corporation (NYSE:DHR), based in Washington, D.C., announced today that its Board of Directors has appointed Elias A. Zerhouni, M.D. to Danaher’s Board of Directors. Dr. Zerhouni served as director of the National Institutes of Health from 2002 to 2008, and currently serves as Senior Advisor at Johns Hopkins University School of Medicine and as Senior Fellow for the Bill and Melinda Gates Foundation Global Health Program. Under his leadership, the NIH embarked on a number of initiatives, chief among them the Roadmap for Medical Research, designed to enhance synergy and collaborative work among all 27 NIH institutes and centers and leading to the passing by the US Congress of the NIH Reform Act of 2006. Other new programs included those designed to foster high-risk but potentially high-impact research, and enhanced support for young career scientists.
For more information contact Dr. Kirstin Henze, Leica Microsystems GmbH Telephone +49 ( 0) 6441/29-2550 or kirstin.henze@leica-microsystems.com
____________________________________________
22 December 2009: Clarient has launched PI3K. PI3K plays a major oncogenic role in many cancer types including glioblastoma multiforme, colon, liver and breast cancer. PI3K somatic mutations were found in 32% of colorectal tumors, 27% of glioblastomas, 25% of gastric cancers, 36% of hepatocellular carcinomas, 40% of breast cancers, 12% of ovarian cancers, and 4% of lung cancers. The common activation of the PI3K-AKT pathway in cancers generally suggests a possible therapeutic opportunity for pharmacologic intervention. Patients with tumors containing PI3K mutations may ultimately benefit from therapy directed at mutant PI3K or its downstream targets and may show a lack of benefit from drugs blocking upstream targets. Testing turnaround time is usually 5-7 days.
For additional questions, please contact Matt Clawson, Allen & Caron, Inc. at 949.474.4300 or click here for more information on Clarient.
___________________________________________
9 October 2009: Inc. magazine has ranked Biocare Medical No. 2984 on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation. The company’s sales growth was 93.1% from 2005-2008. This adds to several honors Biocare has received in recent years including 4 ‘Top of the class’ awards since 2005 for high quality products and service from Advance for Administrators magazine, and ranking as one of the top 50 fastest growing companies in the East Bay. Since its launch in 1997, Biocare Medical has made a significant leap towards achieving its goal of becoming the most trusted source for cancer diagnostics with strong commitment to patient care and the highest quality IHC and molecular pathology products.
For more information contact Mark Cross, Director of Marketing, at mcross@biocare.net or click here.
____________________________________________
16 September 2009: Quantimetrix Corporation announces several newly added urine reagent strip values to its Dipper, Dropper, Dropper Plus, and Dip & Spin inserts. Values for Accutest, Accustrip, Acon Mission, Henry Schein® Urispec™, Macherey Nagel® Medi-Test, and McKesson Medi-Lab™ Performance have been added to expand the utility of the urinalysis control line. Quantimetrix continues to add new urine reagent strip values in an effort to better serve its customers. The Quantimetrix catalog features urinalysis, general and specialty chemistry controls, whole blood, electrophoresis systems, diagnostic assays, and OEM products. The company’s catalog is available upon request by visiting http://www.4qc.com or by calling 1.310.536.0006.
Quantimetrix provides a comparative quality control program called Quantrol™. Free monthly reports are provided for participants allowing each lab to monitor test performance and trend analysis. Quantimetrix Corporation, a pioneer in liquid quality controls, develops and manufactures clinical diagnostic products for global distribution, including Lipoprint®, a device for the separation and measurement of low density lipoprotein (LDL) subfraction cholesterol.
____________________________________________
10 Sept 2009: Milestone, an innovator of rapid microwave tissue processors and digital imaging products, launches the MacroVIEW D, a photographic capture, annotation, and storage system. The MacroVIEW D removes many manual tasks from photographic evidence collection and consolidates digital case assets to free lab personnel for other work. The system is composed of a touch screen computer running image capture and annotation software, a fixed (full body) camera, and a mobile camera. The MacroVIEW D is designed specifically to capture and store digital images of whole bodies, body parts and larger organ systems examined at autopsy or during forensic investigations. Users select from freehand and preset shape drawing tools, editable text tags, voice comments, and video files to annotate case images. Files are automatically collected and organized into individual case folders that can be quickly accessed. All case files are named and numbered sequentially to document the evidence chain.
For more information call 866-995-5300, email info@milestonemed.com or click here.
_______________________________________________
18 June 2009: Photodyne Technologies is a manufacturer of specialized photographic machines for use in grossing, pathology and forensic labs, and other macro photography applications. Our new macro-photography and grossing units have an optional low voltage D.C. operation, for enhanced safety. The units are supplied with top of the line digital cameras, with resolution of 8 to 15 megapixels and higher. The system comes with proprietary software and connects directly to the user’s computer through a USB port, allowing the user to take pictures directly from the computer in real time, with adjustments in the scene as necessary. All major attributes of the camera are controllable from the computer as well.
Once the picture is snapped, the data are transferred to the hard drive through the USB port and stored in the user’s specified location, and the pictures are then ready to be used for lectures and presentations, archiving, email attachments, research and more.
Visit us online at www.photodyne.com or contact us at 800-660-2147 or hrzc@earthlink.net for more information.
_______________________________________________
26 April 2009: Impac Software has named Timothy J. Dolan, Pathology Information System Manager at Roswell Park Cancer Institute in Buffalo, New York as 2009 Laboratory Professional of the Year. The annual award is part of Impac Software’s celebration of National Medical Laboratory Professionals Week, April 19-25, 2009. He was recognized for his 18 years of exceptional service, including managing the implementation of Impac Software’s laboratory information system, PowerPath®.
For more information, please click here, or contact Julie DeSantis, Market Manager, Impac Software 408-830-8083 or jdesantis@impac.com
__________________________________________
20 April 2009: Mopec is pleased to introduce its newest product, 10%Neutral Buffered Formalin. Premixed Neutral Buffered Formalin takes the mess out of mixing and pouring. Shelf life is 2 years. Mopec offers four convenient sizes: 1 Gallon, 5 Gallon Cubitainer, 30 Gallon Drum and a 55 Gallon Drum. For a limited time, Mopec has introductory pricing.
For more information, please click here, contact sales@mopec.com or call one of our friendly and knowledgeable customer service representatives at 800.362.8491.
_______________________________________________
25 February 2009: Voicebrook, a leading provider of integrated speech recognition solutions for healthcare, today announces the appointment of E. Bruce Sopko as Vice President, Sales. Sopko, who brings more than 20 years' experience, has a proven track record of driving market growth for speech recognition technologies in healthcare and brings strong leadership, operational, negotiation, creative and analytical skills.
For more information, please click here or email pathology@voicebrook.com.
_______________________________________________
10 February 2009: Covance is pleased to announce the availability of Collagen XVII antibody. Collagen XVII (BP180) is a transmembrane protein of the cutaneous basement membrane that plays an important role in epidermal-dermal adhesion. It has been associated with inherited bullous skin disease and autoimmune disease, and may also play a role in trophoblast invasion. The launch of Collagen XVII adds to Covance’s growing portfolio of antibodies and detection chemistries.
For more information, please visit www.covance.com.
_____________________________________________
10 February 2009: Vachette Pathology is proud to announce its newly improved website Vachettepathology.com. The website will have more content and more information. The goal of the website will be to concentrate all the knowledge and experience we have into a single database that is more useable for both our current and potential customers.
Vachette Pathology is a practice management firm that specializes in pathology. Currently we work with over 450 pathologists nationwide and are commonly held as the industry leaders in the business of pathology and laboratory management.
If you have any questions or for further information, please contact Mick Raich toll free at 866-407-0763, or email mraich@vachettepathology.com
_____________________________________________
18 September 2008: Invitrogen Corporation has signed an exclusive U.S. distribution agreement with Biocare Medical LLC for the new SPOT-Light® HER2 CISH Kit. The kit received U.S. Food and Drug Administration premarket approval in July, as an aid in the assessment of breast cancer patients for whom trastuzumab (Herceptin®) treatment is being considered.
Approximately one million people worldwide are screened each year for HER2 amplification or over-expression. The importance of genetic tests like HER2 CISH is growing because some targeted cancer therapies (like trastuzumab) are most effective in patients who overexpress the HER2 gene. The primary users will be pathologists, oncologists, and histotechnologists who will determine the best course of treatment for breast cancer patients. The SPOT-Light® test uses standard histology laboratory methods and equipment to yield valuable gene status information.
HER2 – not amplified HER2 - amplified
Per FDA requirements, laboratories must be certified prior to purchasing the SPOT-Light® HER2 CISH Kit for use on patient specimens. One user per laboratory must successfully complete Invitrogen’s HER2 CISH certification program. Full certification details are available by clicking here. After certification, the SPOT-Light® HER2 CISH Kit may be ordered by calling (800) 799-9499 or click here.
For more information, please visit Biocare at www.biocare.net or call 800-799-9499.
_______________________________________________
11 September 2008: AP Easy GYN Cytology Module is set to enter first round beta testing in early September 2008. It is expected to be widely available by November 2008. An updated version of Easy Billing insurance billing application and AP Easy to Easy Billing integration is on track for an early 2009 unveiling. For more information, please telephone 800-647-2263, email info@sbcne.com or click here.
_______________________________________________
10 September 2008: Sakura announces The Tissue-Tek® Xpress® x50. The Tissue-Tek® Xpress® x50 delivers unprecedented productivity and maximizes staff efficiency. The Tissue-Tek® Xpress® x50 processes up to 440 specimens in an 8-hour shift, with the ability to load up to 40 cassettes approximately every 45 minutes. It provides outstanding time and cost savings, as well as increased staff safety, while producing standardized, accurate results paralleling those from overnight processing, allowing same-day diagnosis and, ultimately, improved patient care.
For more information, visit us online (click here), write to mail@sakuraus.com, or call 1-800-725-8723 and press 1 for customer service.
_______________________________________________
23 June 2008: ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that it has entered into a business alliance with Pathology Service Associates, LLC (PSA), a nationwide network affiliation and a principal provider of business services and support to independent pathologist practices. The agreement offers special pricing to the over 400 pathologists affiliated with PSA for ARUP's esoteric molecular oncology and cytogenetics testing services. Additionally, ARUP's proprietary online diagnostic tool, ARUP Consult®, The Physician's Guide to Laboratory Test Selection and Interpretation, will be integrated into PSA's internal Web site for affiliated practices within the next few months.
For more information, click here, then click on News & Information on the right side.
_______________________________________________
18 June 2007: Ventana Medical Systems announces its new CONFIRM anti-CD3 (2GV6) – the latest exciting advancement in moving from mouse to Rabbit Monoclonal Primary Antibodies.
CONFIRM anti-CD3 (2GV6) detects CD3 antigen expressed in the cytoplasmic membrane of normal and neoplastic T-cells.
To read a research paper about this product click here. For more information visit Ventanamed.com or call 800.227.2155.
End of New Products and Services page